Cell and gene therapy development is advancing toward commercialization faster than most manufacturing,

process development, analytical, and CMC teams can keep pace. This is especially evident as South Korea’s first

CAR‑T therapy enters the market.

Amid ongoing regulatory uncertainty, the primary challenge lies not in clinical performance but in supply chain and process readiness, making now a critical window to build robust, scalable, and compliant manufacturing strategies.

Join this workshop to gain key insights on:

• Systemic Agility: Mitigating material complexities and supply network volatility
• Clinical development of chimeric antigen receptor T-cell therapy manufacturing, formulation and administration
• Ensuring safety and cost efficiency in the scaled manufacturing of cell therapy products